Clinical trials: Daratumumab
Multiple Myeloma
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) in combination with…
- Trial name
- CyBorD-Dara (NCT02955810)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- National University of Ireland, Galway, Ireland
Multiple Myeloma
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.
- Trial name
- REBUILD (NCT03475628)
- Testing
- Daratumumab
- Where
- Greece
- Volunteers
- 57 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood.
- Trial name
- DARA (NCT02419118)
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Vejle Hospital
Multiple Myeloma
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability and safety of Daratumumab in Japanese participants with relapsed (the return of a medical problem) or refractory (not responding to treatment) multiple myeloma (cancer of…
- Trial name
- NCT02116569
- Testing
- Daratumumab
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.